Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Patterns of Survival in Patients with Aggressive B-Cell Lymphoma Treated with CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CART) As Second Versus Later Line of Therapy

Blood (2024) 144 (Supplement 1): 612.

https://doi.org/10.1182/blood-2024-202665

Published: 2024

Journal Articles

Efficacy, Toxicity, and Predictors of Outcomes with CD3-CD20 Bi-Specific Antibodies Post CAR T-Cell Failure for Aggressive B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 473.

https://doi.org/10.1182/blood-2024-201626

Published: 2024

Journal Articles

Frontline R-CHOP and BR Have Similar Outcomes By SUV max in Follicular Lymphoma

Blood (2024) 144 (Supplement 1): 3007.

https://doi.org/10.1182/blood-2024-202088

Published: 2024

Journal Articles

Clinical Features and Outcomes of Patients with T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: A Single-Center Analysis

Jason T Romancik, Katelin Baird, Angelo Thomas Marra, Amelia Langston, Pamela B. Allen, Jonathon B. Cohen, Jean L. Koff, Mary Jo Lechowicz, Jeffrey M. Switchenko, Kristie A. Blum

Blood (2024) 144 (Supplement 1): 1717.

https://doi.org/10.1182/blood-2024-211784

Published: 2024

Journal Articles

Categorization and Impact of Bridging Therapy Prior to CAR T-Cell Infusion in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Pranav Santapuram, Jason T Romancik, Jonathon B Cohen, Melissa Kives, Manali Rupji, Javier Pinilla-Ibarz, Kami J. Maddocks, Craig A. Portell, Joanna M. Rhodes, Brian K. Link

Blood (2024) 144 (Supplement 1): 1744.

https://doi.org/10.1182/blood-2024-204002

Published: 2024

Journal Articles

Intermediate Dose Post-Transplant Cyclophosphamide Is Associated with Faster Engraftment and Similar Other Outcomes When Compared with Full Dose Post-Transplant Cyclophosphamide Among Patients Undergoing Allogeneic Transplantation: A Single Center Retrospective Analysis

Joseph Rimando, Michel Conn, William Blum, Jason T Romancik, Colin Vale, Amelia Langston, Edmund K. Waller, Kevin Hall

Blood (2024) 144 (Supplement 1): 3521.

https://doi.org/10.1182/blood-2024-198921

Published: 2024

Journal Articles

A Phase 1, Open-Label, Multicenter Study of Treatment with ACE1831, Comprised of Allogeneic Gamma Delta T Cells Conjugated to an Anti-CD-20 Antibody, in Patients (Pts) with B-Cell Relapsed/Refractory Non-Hodgkin's Lymphoma (R/R NHL)

Don A. Stevens, Jason T Romancik, Rushang D. Patel, Ranjit Nair, Janet Pan, Stephanie Chien, Ifeoluwapo Olorunyomi, Sai-Wen Tang, Heather Kelley, Jerry Liu, Michael Kurman

Blood (2024) 144 (Supplement 1): 7251.

https://doi.org/10.1182/blood-2024-200120

Published: 2024

Journal Articles

Multicenter Study to Assess the Outcomes and Prognosis of Richter's Transformation in the Era of Novel Agents and Cell Therapy

Fateeha Furqan, Katelin Baird, Merve Kacar, Annika S Surapaneni, Ulrich Kemmo Tsafack, Aniko Szabo, Jakub Svoboda, Brian T. Hill, Jason T. Romancik, Nirav N. Shah

Blood (2023) 142 (Supplement 1): 4486.

https://doi.org/10.1182/blood-2023-186703

Published: 2023

Journal Articles

Patterns of Care and Prognostic Modeling Following Follicular Lymphoma Transformation to Aggressive B-Cell Lymphoma: An Analysis from the LEO Consortium

Jonathan R Day, Melissa C. Larson, Carla Casulo, Urshila Durani, Yucai Wang, Dai Chihara, Loretta J. Nastoupil, Brad S. Kahl, Peter Martin, Izidore S. Lossos, Jason T. Romancik, Amy Ayers, Richard Burack, Thomas M. Habermann, James R. Cerhan, Christopher R. Flowers, Matthew J. Maurer, Brian K. Link

Blood (2023) 142 (Supplement 1): 3111.

https://doi.org/10.1182/blood-2023-179650

Published: 2023

Journal Articles

Loncastuximab in High-Risk and Heavily-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real World Analysis from 21 US Centers

Blood (2023) 142 (Supplement 1): 312.

https://doi.org/10.1182/blood-2023-174257

Published: 2023

Journal Articles

The Presence of Bulky Disease and/or Very High LDH Defines a High-Risk Subset of IPI 1-2 for Eligibility in Clinical Trials of Newly Diagnosed Aggressive B-Cell Lymphoma

Matthew J. Maurer, Arushi Khurana, Umar Farooq, Jason T. Romancik, Jonathan W. Friedberg, Izidore S. Lossos, Brad S. Kahl, Peter Martin, Dai Chihara, Andrew L. Feldman, Sergei Syrbu, David L Jaye, Elliot Cahn, Thomas M. Habermann, Brian K. Link, James R. Cerhan, Christopher R. Flowers, Loretta J. Nastoupil, Grzegorz S. Nowakowski

Blood (2023) 142 (Supplement 1): 4512.

https://doi.org/10.1182/blood-2023-187350

Published: 2023

Journal Articles

Outcomes of Sequential CD19-Directed Therapies in Relapsed and Refractory Large B Cell Lymphoma

Blood (2023) 142 (Supplement 1): 3136.

https://doi.org/10.1182/blood-2023-182204

Published: 2023

Journal Articles

Exploration of Language As a Barrier to the Assessment and Management of CAR T-Cell Therapy Associated Toxicities

Blood (2023) 142 (Supplement 1): 2407.

https://doi.org/10.1182/blood-2023-183041

Published: 2023

Journal Articles

Overall Survival Following First and Second Relapse of DLBCL Treated with Therapies Including Autologous Transplant and CAR-T Cells: Results from the Lion Prospective Observational Registry

Greg Kirkpatrick, Jeffrey M. Switchenko, Melissa Kives, Katelin Baird, Kami J. Maddocks, Jason T. Romancik, Deborah M. Stephens, Harsh Shah, Javier Pinilla-Ibarz, Julio C Chavez, Matthew Matasar, Craig A. Portell, Michelle Churchman, Jonathon B. Cohen, Umar Farooq, Brian K. Link

Blood (2023) 142 (Supplement 1): 6325.

https://doi.org/10.1182/blood-2023-187198

Published: 2023

Journal Articles

Immune Reconstitution and Infection Patterns Following CAR T-Cell Therapy in Patients with Aggressive Lymphoma

Blood (2023) 142 (Supplement 1): 1738.

https://doi.org/10.1182/blood-2023-183011

Published: 2023

Journal Articles

Poor Survival Outcomes of Checkpoint Inhibitors for B-Cell Lymphomas Relapsing after or Refractory to CAR T-Cell Therapy: A Real-World Cohort from 15 U.S. Academic Institutions

Blood (2022) 140 (Supplement 1): 1328–1331.

https://doi.org/10.1182/blood-2022-157829

Published: 2022

Journal Articles

Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-Cell Lymphomas Treated with Chimeric Antigen Receptor T-Cell (CART) Therapy

Blood (2022) 140 (Supplement 1): 10955–10957.

https://doi.org/10.1182/blood-2022-160431

Published: 2022

Journal Articles

Evaluating the Impact of Lab-Based Eligibility Criteria By Race/Ethnicity in Frontline Clinical Trials for Diffuse Large B-Cell Lymphoma (DLBCL): A LEO Cohort Analysis

Arushi Khurana, Raphael Mwangi, Loretta J. Nastoupil, Patrick M. Reagan, Umar Farooq, Jason T. Romancik, Timothy J. McDonnell, Shaun M Riska, Izidore S. Lossos, Brad S. Kahl, Peter Martin, Thomas E. Witzig, James R. Cerhan, Christopher R. Flowers, Matthew J. Maurer, Grzegorz S. Nowakowski

Blood (2022) 140 (Supplement 1): 2056–2058.

https://doi.org/10.1182/blood-2022-169433

Published: 2022

Journal Articles

Favorable Overall Survival Following First and Second Relapse of MCL with Availability of Novel Therapies: Results from the Lion Prospective Observational Registry

David A. Bond, Jason T. Romancik, Jeffrey M. Switchenko, Brielle Berkowitz, Jonathan R Day, Umar Farooq, Sabarish Ayyappan, Katelin Baird, Michelle L. Churchman, Andrew M. Evens, Bijal D. Shah, Craig A. Portell, Kami J. Maddocks, Brian K. Link, Jonathon B. Cohen, Deborah M. Stephens

Blood (2022) 140 (Supplement 1): 6509–6511.

https://doi.org/10.1182/blood-2022-160306

Published: 2022

Journal Articles

Tafasitamab and Lenalidomide in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): Real World Outcomes in a Multicenter Retrospective Study

David Qualls, Michael J Buege, Phuong Dao, Paolo F. Caimi, Sarah C. Rutherford, Graham Wehmeyer, Jason T. Romancik, Lori A. Leslie, Mwanasha H. Merrill, Jennifer L. Crombie, Behzad Amoozgar, Brad S. Kahl, David A. Bond, Kami J. Maddocks, Michelle Okwali, Venkatraman Seshan, Gilles Salles, Connie Lee Batlevi

Blood (2022) 140 (Supplement 1): 787–789.

https://doi.org/10.1182/blood-2022-167620

Published: 2022

NARROW

Patterns of Survival in Patients with Aggressive B-Cell Lymphoma Treated with CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CART) As Second Versus Later Line of Therapy

Efficacy, Toxicity, and Predictors of Outcomes with CD3-CD20 Bi-Specific Antibodies Post CAR T-Cell Failure for Aggressive B-Cell Lymphoma

Frontline R-CHOP and BR Have Similar Outcomes By SUV max in Follicular Lymphoma

Clinical Features and Outcomes of Patients with T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: A Single-Center Analysis

Categorization and Impact of Bridging Therapy Prior to CAR T-Cell Infusion in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Intermediate Dose Post-Transplant Cyclophosphamide Is Associated with Faster Engraftment and Similar Other Outcomes When Compared with Full Dose Post-Transplant Cyclophosphamide Among Patients Undergoing Allogeneic Transplantation: A Single Center Retrospective Analysis

A Phase 1, Open-Label, Multicenter Study of Treatment with ACE1831, Comprised of Allogeneic Gamma Delta T Cells Conjugated to an Anti-CD-20 Antibody, in Patients (Pts) with B-Cell Relapsed/Refractory Non-Hodgkin's Lymphoma (R/R NHL)

Multicenter Study to Assess the Outcomes and Prognosis of Richter's Transformation in the Era of Novel Agents and Cell Therapy

Patterns of Care and Prognostic Modeling Following Follicular Lymphoma Transformation to Aggressive B-Cell Lymphoma: An Analysis from the LEO Consortium

Loncastuximab in High-Risk and Heavily-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real World Analysis from 21 US Centers

The Presence of Bulky Disease and/or Very High LDH Defines a High-Risk Subset of IPI 1-2 for Eligibility in Clinical Trials of Newly Diagnosed Aggressive B-Cell Lymphoma

Outcomes of Sequential CD19-Directed Therapies in Relapsed and Refractory Large B Cell Lymphoma

Exploration of Language As a Barrier to the Assessment and Management of CAR T-Cell Therapy Associated Toxicities

Overall Survival Following First and Second Relapse of DLBCL Treated with Therapies Including Autologous Transplant and CAR-T Cells: Results from the Lion Prospective Observational Registry

Immune Reconstitution and Infection Patterns Following CAR T-Cell Therapy in Patients with Aggressive Lymphoma

Poor Survival Outcomes of Checkpoint Inhibitors for B-Cell Lymphomas Relapsing after or Refractory to CAR T-Cell Therapy: A Real-World Cohort from 15 U.S. Academic Institutions

Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-Cell Lymphomas Treated with Chimeric Antigen Receptor T-Cell (CART) Therapy

Evaluating the Impact of Lab-Based Eligibility Criteria By Race/Ethnicity in Frontline Clinical Trials for Diffuse Large B-Cell Lymphoma (DLBCL): A LEO Cohort Analysis

Favorable Overall Survival Following First and Second Relapse of MCL with Availability of Novel Therapies: Results from the Lion Prospective Observational Registry

Tafasitamab and Lenalidomide in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): Real World Outcomes in a Multicenter Retrospective Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only